A unifying mutation in chronic myeloproliferative disorders

New England Journal of Medicine

Volumn 352, Issue 17, 2005, Pages 1744-1746

  Goldman, John M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; PROTEIN TYROSINE KINASE;

CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; ERYTHROLEUKEMIA; GENETIC ASSOCIATION; GENETIC DISORDER; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MUTATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA;

CYTOKINES; HUMANS; JANUS KINASE 2; LOSS OF HETEROZYGOSITY; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYCYTHEMIA VERA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 17644417451     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp058083     Document Type: Short Survey

References (4)

1. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol 2004;5:253.
2. James C, Ugo V, Le Couedic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (in press).
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (in press).
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.